氨柔比星
外观
![]() | |
臨床資料 | |
---|---|
AHFS/Drugs.com | 国际药品名称 |
给药途径 | IV |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
识别信息 | |
| |
CAS号 | 110267-81-7 ![]() |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化学信息 | |
化学式 | C25H25NO9 |
摩尔质量 | 483.47 g·mol−1 |
3D模型(JSmol) | |
| |
|
氨柔比星(INN:amrubicin;开发代号:SM-5887)是一种用于治疗肺癌的蒽环类药物。[1]它自2002年起由住友制药以商品名Calsed在日本销售。[2]
氨柔比星通过抑制拓扑异构酶II发挥作用,并在临床试验中与拓扑替康(拓扑异构酶I抑制剂)进行了比较。[3][4]
氨柔比星是第一个通过从头合成的蒽环类衍生物,由住友化学家的科学家于1989年首次发表。[7]
参考资料
[编辑]- ^ Ueoka H, Ohnoshi T, Kimura I. [New anthracycline analogues in the treatment of lung cancer]. Gan to Kagaku Ryoho. November 1992, 19 (13): 2146–9. PMID 1332624 (日语).
- ^ Sumitomo Pharmaceuticals Co., Ltd. CALSED for Injection (English) (PDF). 2003 [2008-08-17]. [失效連結]
- ^ Celgene Corporation. Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer. 2008 [2009-07-10]. (原始内容存档于2013-01-19).
- ^ Medical News Today. Pharmion's Amrubicin Shows Encouraging Results Compared To Standard Of Care In Second Line Treatment Of Small Cell Lung Cancer. 2007 [2009-07-10].
- ^ Ohmori H, Tsushima T, Kobashi K. [Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma]. Gan to Kagaku Ryoho. April 1996, 23 (5): 601–6. PMID 8678519 (日语).
- ^ Tsushima K, Sakata Y, Munakata A, et al. [A phase II study of SM-5887 for advanced gastric cancer]. Gan to Kagaku Ryoho. June 1991, 18 (7): 1151–4. PMID 1647150 (日语).
- ^ Hanada M. Amrubicin, Chapter 6 in Case Studies in Modern Drug Discovery and Development. Eds. Huang X and Aslanian RG. John Wiley & Sons, 2012 ISBN 9780470601815 P 106
|